This study demonstrates experimentally that pre-stroke pharmacological targeting of obesity by GLP-1R and NPY2R activation in type 2 diabetes enhances stroke recovery, without effects additional to weight loss mediated by the treatments. The gene discussed is NPY2R; the disease is type 2 diabetes mellitus.